The Bromodomain: A New Target in Emerging Epigenetic Medicine

The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein–protein interactions in...

Full description

Saved in:
Bibliographic Details
Published inACS chemical biology Vol. 11; no. 3; pp. 598 - 608
Main Authors Smith, Steven G, Zhou, Ming-Ming
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 18.03.2016
Subjects
Conserved Sequence
Drug Delivery Systems
Epigenesis, Genetic
Humans
Lysine - chemistry
Lysine - metabolism
Protein Domains
Receptors, Fc
Online AccessGet full text

Cover

More Information
Summary:The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein–protein interactions in the cell, ranging from substrate recruitment for histone acetyltransferases (HATs) to aiding in multiple-protein complex assembly for gene transcriptional activation or suppression in chromatin. In recent years, considerable efforts have been made to develop chemical inhibitors of these bromodomains in an effort to probe their cellular functions. Potent and selective inhibitors have been extensively developed for one group of the bromodomain family termed BET proteins that consist of tandem bromodomains followed by an extra terminal domain. Drug developers are actively designing inhibitors of other bromodomains and working to move the most successful inhibitors into the clinic.
ISSN:1554-8929
1554-8937
DOI:10.1021/acschembio.5b00831